Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit, which was wound down last year as part of a major restructuring drive.

诺和诺德已经出售了其现已解散的细胞治疗部门中一个旗舰候选药物的权利，该部门于去年作为重大重组计划的一部分被关闭。

Cellular Intelligence, which is backed by Meta chief executive Mark Zuckerberg, has acquired rights to STEM-PD, an allogeneic cell therapy for Parkinson's disease that has cleared early-stage clinical testing with the groundwork laid for phase 2, proof-of-concept testing. The therapy, based on donor stem cells, is designed to restore the dopamine-producing neurons that degenerate in Parkinson's..

元首席执行官马克·扎克伯格支持的Cellular Intelligence公司已获得STEM-PD的授权，这是一种用于治疗帕金森病的同种异体细胞疗法，该疗法已完成早期临床测试，并为第二阶段的概念验证测试奠定了基础。这种基于捐赠者干细胞的疗法旨在恢复在帕金森病中退化的多巴胺生成神经元。

Financial terms of the deal have not been disclosed, but Novo Nordisk has made an equity investment in Boston-based Cellular Intelligence, which said the deal is a 'defining moment' for the company.

交易的财务条款尚未披露，但诺和诺德已对总部位于波士顿的细胞智能公司进行了股权投资，该公司表示这笔交易是公司的“决定性时刻”。

Last October, Novo Nordisk announced it was winding down its cell therapy unit – laying off around 250 workers – as it reacted to an increasingly competitive and challenging environment for its diabetes and obesity therapies, which have driven growth in recent years.

去年十月，诺和诺德宣布将缩减其细胞治疗部门，并裁员约250人，以此应对糖尿病和肥胖症疗法领域日益激烈的竞争和充满挑战的环境。这些疗法近年来一直是公司增长的主要驱动力。

The restructuring, which will claim around 9,000 jobs when completed, is aimed at sharpening its focus and simplifying structures. While cell therapy did not make the cut, Novo Nordisk said it was looking for partners to advance the programmes, which also include candidates for type 1 diabetes and heart disease..

该重组计划完成后将裁减约9,000个工作岗位，旨在加强其专注力并简化结构。虽然细胞治疗未被列入其中，但诺和诺德表示正在寻找合作伙伴以推进这些项目，其中包括针对1型糖尿病和心脏病的候选药物。

Ahead of that announcement, it terminated a

在那项声明发布之前，它终止了

$598 million alliance

5.98亿美元的联盟

with Japanese biotech Heartseed, first signed in 2021, to develop a cell therapy for

与日本生物技术公司Heartseed合作，首次签约于2021年，旨在开发一种细胞疗法。

advanced heart failure

晚期心力衰竭

.

。

The Cellular Intelligence deal has rescued the Parkinson's programme, and the biotech said it now plans to use its AI platform to usher the treatment through further clinical development, build up manufacturing, and – hopefully – bring the much-needed therapy onto the market.

Cellular Intelligence 的交易挽救了帕金森病项目，这家生物技术公司表示，现在计划利用其人工智能平台推动该疗法进入进一步的临床开发、建立生产，并希望将这种急需的疗法推向市场。

The data from the programme will ‌be

该计划的数据将被

⁠

used to further train Cellular Intelligence's AI model.

用于进一步训练蜂窝智能的AI模型。

'We are building an AI-native, fully integrated therapeutics company,' said Cellular Intelligence chief executive and co-founder Micha Breakstone in a statement.

“我们正在建立一家AI原生的、完全集成的治疗公司，”Cellular Intelligence首席执行官兼联合创始人米查·布雷克斯通在一份声明中表示。

'The same platform that learns how cells respond to signals can help design better protocols, improve manufacturability, optimise functional dose, and deepen our understanding of how development decisions connect to clinical outcomes,' he added.

“同样的平台，既可以学习细胞如何响应信号，又可以帮助设计更好的方案，提高可制造性，优化功能剂量，并加深我们对发育决策与临床结果之间联系的理解，”他补充道。

'STEM-PD gives us the ideal proving ground for that vision.'

“STEM-PD 为我们实现这一愿景提供了理想的试验场。”

Cellular Intelligence, previously known as Somite, raised $47 million in a Series A last year led by Khosla Ventures for its foundation model, which it says can produce 'any cell type for any person' and could create 'a foundry of human spare parts, enabling cures for a wide range of diseases.'

去年，细胞智能公司（Cellular Intelligence，前身为Somite）在Khosla Ventures领投的A轮融资中筹集了4700万美元，用于其基础模型。该公司称该模型可以“为任何人生产任何类型的细胞”，并可能创造出“人体备用器官的铸造厂，为广泛疾病提供治愈的可能性”。